Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) PT at $20.58

Bausch + Lomb Co. (NYSE:BLCO) has been given a consensus rating of “Hold” by the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $20.58.

A number of brokerages have recently commented on BLCO. Wells Fargo & Company raised their target price on shares of Bausch + Lomb from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Citigroup lowered shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Morgan Stanley lowered Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Monday, December 2nd. Finally, Stifel Nicolaus lifted their price target on Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a report on Monday, September 23rd.

Bausch + Lomb Stock Performance

Bausch + Lomb stock opened at $17.91 on Friday. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The company has a market capitalization of $6.31 billion, a price-to-earnings ratio of -17.06, a PEG ratio of 1.74 and a beta of 0.47. The stock has a fifty day moving average of $19.17 and a two-hundred day moving average of $17.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company posted $0.22 EPS. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. On average, analysts anticipate that Bausch + Lomb will post 0.6 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

A number of large investors have recently added to or reduced their stakes in BLCO. Fore Capital LLC lifted its position in shares of Bausch + Lomb by 90.2% during the 2nd quarter. Fore Capital LLC now owns 42,180 shares of the company’s stock valued at $612,000 after acquiring an additional 20,000 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Bausch + Lomb by 53.9% during the second quarter. Dimensional Fund Advisors LP now owns 67,690 shares of the company’s stock worth $984,000 after purchasing an additional 23,714 shares during the period. Gabelli Funds LLC lifted its holdings in shares of Bausch + Lomb by 25.0% during the second quarter. Gabelli Funds LLC now owns 390,000 shares of the company’s stock valued at $5,663,000 after purchasing an additional 78,000 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Bausch + Lomb in the 2nd quarter valued at $1,911,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Bausch + Lomb in the second quarter worth about $580,000. 11.07% of the stock is currently owned by institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.